Literature DB >> 31444481

Protozoan persister-like cells and drug treatment failure.

Michael P Barrett1, Dennis E Kyle2, L David Sibley3, Joshua B Radke3, Rick L Tarleton2.   

Abstract

Antimicrobial treatment failure threatens our ability to control infections. In addition to antimicrobial resistance, treatment failures are increasingly understood to derive from cells that survive drug treatment without selection of genetically heritable mutations. Parasitic protozoa, such as Plasmodium species that cause malaria, Toxoplasma gondii and kinetoplastid protozoa, including Trypanosoma cruzi and Leishmania spp., cause millions of deaths globally. These organisms can evolve drug resistance and they also exhibit phenotypic diversity, including the formation of quiescent or dormant forms that contribute to the establishment of long-term infections that are refractory to drug treatment, which we refer to as 'persister-like cells'. In this Review, we discuss protozoan persister-like cells that have been linked to persistent infections and discuss their impact on therapeutic outcomes following drug treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31444481      PMCID: PMC7024564          DOI: 10.1038/s41579-019-0238-x

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  141 in total

Review 1.  Defining the frontiers between antifungal resistance, tolerance and the concept of persistence.

Authors:  Eric Delarze; Dominique Sanglard
Journal:  Drug Resist Updat       Date:  2015-10-30       Impact factor: 18.500

Review 2.  Persister cells, dormancy and infectious disease.

Authors:  Kim Lewis
Journal:  Nat Rev Microbiol       Date:  2006-12-04       Impact factor: 60.633

Review 3.  Molecular mechanisms of antibiotic resistance.

Authors:  Jessica M A Blair; Mark A Webber; Alison J Baylay; David O Ogbolu; Laura J V Piddock
Journal:  Nat Rev Microbiol       Date:  2014-12-01       Impact factor: 60.633

Review 4.  Formation, physiology, ecology, evolution and clinical importance of bacterial persisters.

Authors:  Bram Van den Bergh; Maarten Fauvart; Jan Michiels
Journal:  FEMS Microbiol Rev       Date:  2017-05-01       Impact factor: 16.408

Review 5.  Molecular mechanisms and clinical implications of bacterial persistence.

Authors:  Joran Elie Michiels; Bram Van den Bergh; Natalie Verstraeten; Jan Michiels
Journal:  Drug Resist Updat       Date:  2016-10-15       Impact factor: 18.500

Review 6.  Leishmaniasis: complexity at the host-pathogen interface.

Authors:  Paul Kaye; Phillip Scott
Journal:  Nat Rev Microbiol       Date:  2011-07-11       Impact factor: 60.633

Review 7.  Microbial persistence and the road to drug resistance.

Authors:  Nadia R Cohen; Michael A Lobritz; James J Collins
Journal:  Cell Host Microbe       Date:  2013-06-12       Impact factor: 21.023

Review 8.  Persistent bacterial infections and persister cells.

Authors:  Robert A Fisher; Bridget Gollan; Sophie Helaine
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

Review 9.  Tumor cell dormancy as an adaptive cell stress response mechanism.

Authors:  Laura Vera-Ramirez; Kent W Hunter
Journal:  F1000Res       Date:  2017-12-14

Review 10.  Drug resistance in eukaryotic microorganisms.

Authors:  Alan H Fairlamb; Neil A R Gow; Keith R Matthews; Andrew P Waters
Journal:  Nat Microbiol       Date:  2016-06-24       Impact factor: 17.745

View more
  29 in total

Review 1.  Long non-coding RNAs as possible therapeutic targets in protozoa, and in Schistosoma and other helminths.

Authors:  Gilbert O Silveira; Helena S Coelho; Murilo S Amaral; Sergio Verjovski-Almeida
Journal:  Parasitol Res       Date:  2021-12-03       Impact factor: 2.289

Review 2.  Paving the Way: Contributions of Big Data to Apicomplexan and Kinetoplastid Research.

Authors:  Robyn S Kent; Emma M Briggs; Beatrice L Colon; Catalina Alvarez; Sara Silva Pereira; Mariana De Niz
Journal:  Front Cell Infect Microbiol       Date:  2022-06-06       Impact factor: 6.073

3.  Alkyne modified purines for assessment of activation of Plasmodium vivax hypnozoites and growth of pre-erythrocytic and erythrocytic stages in Plasmodium spp.

Authors:  Alona Botnar; Grant Lawrence; Steven P Maher; Amélie Vantaux; Benoît Witkowski; Justine C Shiau; Emilio F Merino; David De Vore; Christian Yang; Cameron Murray; Maria B Cassera; James W Leahy; Dennis E Kyle
Journal:  Int J Parasitol       Date:  2022-04-18       Impact factor: 4.330

4.  A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease.

Authors:  Juan M Bustamante; Fernando Sanchez-Valdez; Angel M Padilla; Brooke White; Wei Wang; Rick L Tarleton
Journal:  Sci Transl Med       Date:  2020-10-28       Impact factor: 17.956

5.  In Vitro Potently Active Anti-Plasmodium and Anti-Toxoplasma Mongolian Plant Extracts.

Authors:  Orkhon Banzragchgarav; Javzan Batkhuu; Punsantsogvoo Myagmarsuren; Badgar Battsetseg; Banzragch Battur; Yoshifumi Nishikawa
Journal:  Acta Parasitol       Date:  2021-05-23       Impact factor: 1.440

6.  Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas' Disease.

Authors:  Marta L Lima; Lindsay B Tulloch; Victoriano Corpas-Lopez; Sandra Carvalho; Richard J Wall; Rachel Milne; Eva Rico; Stephen Patterson; Ian H Gilbert; Sonia Moniz; Lorna MacLean; Leah S Torrie; Carmine Morgillo; David Horn; Fabio Zuccotto; Susan Wyllie
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

7.  Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection.

Authors:  Lieselotte Van Bockstal; Dimitri Bulté; Sarah Hendrickx; Jovana Sadlova; Petr Volf; Louis Maes; Guy Caljon
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-05-01       Impact factor: 4.077

Review 8.  Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Authors:  Arijit Bhattacharya; Audrey Corbeil; Rubens L do Monte-Neto; Christopher Fernandez-Prada
Journal:  Genes (Basel)       Date:  2020-06-29       Impact factor: 4.096

Review 9.  Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.

Authors:  Katrien Van Bocxlaer; Simon L Croft
Journal:  RSC Med Chem       Date:  2021-01-07

10.  Identification of Essential Oils Including Garlic Oil and Black Pepper Oil with High Activity against Babesia duncani.

Authors:  Yumin Zhang; Chunxiang Bai; Wanliang Shi; Hector Alvarez-Manzo; Ying Zhang
Journal:  Pathogens       Date:  2020-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.